Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts W/Chronic Myeloid Leukemia

a study on Chronic Myeloid Leukemia Leukemia

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
study ends around
Principal Investigator
by Mahtab Jafari (uci)

Description

Summary

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Official Title

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia

Details

The purpose of this pilot study is to explore the association between personality and adherence to a specific type of oral cancer medication - tyrosine kinase inhibitor (TKI) - in patients with chronic myeloid leukemia (CML). 75 individuals with chronic phase CML who are being treated with TKIs will be recruited. Consenting patients will participate in a focused interview where TKI adherence, personality type, and quality of life and symptom burden will be assessed using validated questionnaires. Information on treatment response and the treating physician's perception of TKI adherence will be obtained from the electronic health record.

Keywords

Chronic Myeloid Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Interviews as Topic, Interview

Eligibility

You can join if…

Open to people ages 18 years and up

  • 18 years of age or older
  • Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
  • Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
  • A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
  • A member of a patient support group organized by the CML Buster Foundation
  • Do not meet any of the criteria listed under "Exclusion Requirements"

You CAN'T join if...

  • Unable to read and speak English
  • Impaired decisional capacity to consent

Location

  • Chao Family Comprehensive Cancer Center University of California, Irvine accepting new patients
    Orange California 92868 United States

Lead Scientist at University of California Health

  • Mahtab Jafari (uci)
    Professor, Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences. Authored (or co-authored) 45 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT06229860
Study Type
Observational
Participants
Expecting 75 study participants
Last Updated
Contact us about this trial